Journal

Current radiopharmaceuticals
ISSN: 1874-4729
Titre abrégé: Curr Radiopharm
Pays: United Arab Emirates
ID NLM: 101468718

Informations de publication

Date de publication:
2022
Historique:
received: 05 05 2020
revised: 27 10 2020
accepted: 05 11 2020
pubmed: 6 1 2021
medline: 13 4 2022
entrez: 5 1 2021
Statut: ppublish

Résumé

Nimotuzumab is a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, nowadays used for tumour immunochemotherapy. This study aimed to label the conjugate DOTA-nimotuzumab with yttrium-90, in order to provide a β- emitting radioimmunoconjugate ( The synthesis of 90Y-DOTA-nimotuzumab was performed in two days. Nimotuzumab was conjugated with a 50-fold excess of DOTA and then labelled with 90Y3+. The The radioimmunoconjugate The optimized conditions for a mild and easy preparation of

Sections du résumé

BACKGROUND BACKGROUND
Nimotuzumab is a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, nowadays used for tumour immunochemotherapy. This study aimed to label the conjugate DOTA-nimotuzumab with yttrium-90, in order to provide a β- emitting radioimmunoconjugate (
METHODS METHODS
The synthesis of 90Y-DOTA-nimotuzumab was performed in two days. Nimotuzumab was conjugated with a 50-fold excess of DOTA and then labelled with 90Y3+. The
RESULTS RESULTS
The radioimmunoconjugate
CONCLUSIONS CONCLUSIONS
The optimized conditions for a mild and easy preparation of

Identifiants

pubmed: 33397277
pii: CRP-EPUB-113035
doi: 10.2174/1874471013999210104220031
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Monoclonal, Humanized 0
Antineoplastic Agents 0
Heterocyclic Compounds 0
Immunoconjugates 0
Organometallic Compounds 0
Radiopharmaceuticals 0
Yttrium Radioisotopes 0
yttrium(III)-1,4,7,10-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid 0
Yttrium-90 1K8M7UR6O1
nimotuzumab 6NS400BXKH

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

32-39

Subventions

Organisme : Fondo di Ateneo Sapienza
ID : RM11715C7D2B14C5

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Teresa Scotognella (T)

Unit of Nuclear Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.

Daria Maccora (D)

Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Roma, Italy.

Isabella Bruno (I)

Unit of Nuclear Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.

Marco Chinol (M)

Unit of Nuclear Medicine, Istituto Europeo di Oncologia, Milano, Italy.

Massimo Castagnola (M)

Laboratorio di Proteomica e Metabonomica - IRCCS Fondazione Santa Lucia, Italy.

Francesco Collamati (F)

Istituto Nazionale di Fisica Nucleare, Roma, Italy.

Carlo Mancini-Terraciano (C)

Istituto Nazionale di Fisica Nucleare, Roma, Italy.
Department of Physics, Università Sapienza, Roma, Italy.

Silvio Morganti (S)

Istituto Nazionale di Fisica Nucleare, Roma, Italy.

Valerio Bocci (V)

Istituto Nazionale di Fisica Nucleare, Roma, Italy.

Elena Solfaroli Camillocci (ES)

Istituto Nazionale di Fisica Nucleare, Roma, Italy.
Department of Physics, Università Sapienza, Roma, Italy.

Dante Rotili (D)

Department of Chemistry and Technologies of Drugs, "Sapienza" University of Rome, 00185 Rome, Italy.

Antonella Cartoni (A)

Department of Chemistry, "Sapienza" University of Rome, 00185 Rome, Italy.

Ilaria Fratoddi (I)

Department of Chemistry, "Sapienza" University of Rome, 00185 Rome, Italy.

Federica Marini (F)

Institute of Biochemistry and Clinical Biochemistry, Università Cattolica del Sacro Cuore, Rome, 00168, Italy.

Iole Venditti (I)

Department of Sciences, Università di Roma Tre, Roma, Italy.

Riccardo Faccini (R)

Istituto Nazionale di Fisica Nucleare, Roma, Italy.
Department of Physics, Università Sapienza, Roma, Italy.

Alessandro Giordano (A)

Unit of Nuclear Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma,Italy.
Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Roma, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH